Good solubility and stability of HA-PTX was obtained by one step method of directly linking the PTX to HA via the ester bond.
The tLyP-1 was used to modify HA-PTX and guided the formed conjugate to penetrate multiple bio-barriers into tumor cells.
The tLyP-1 expanded the anticancer scope of tLyP-1-HA-PTX from tumor cells expressing CD44 to those of expressing NRP1.
Good stability and safety of conjugates were proved via FT-IR, 1H NMR, in vitro stability studies and hemolysis test.
Enhanced targeting and accumulation of conjugates were certified by in vitro cellular uptake studies.